Cogent Biosciences will present a poster on bezuclastinib at the AAAAI Annual Meeting, focusing on long-term symptomatic benefits in NonAdvSM patients.
BioAtla's ozuriftamab vedotin Phase 2 trial shows a 9-month median overall survival in heavily pretreated head and neck cancer patients, indicating potential efficacy.
BioAtla's evalstotug (BA3071), a conditionally active anti-CTLA-4 biologic, demonstrates potential in treating advanced solid tumors, with updated Phase 1 study results to be presented at SITC 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.